Biogen (BIIB) Stock Insights
BIIB$245.16-7.57 -2.99%
$36.22B
Market Cap
44.41
P/E
19.86
Forward P/E
37
Score
Biogen (BIIB) Stock Insights
BIIB price $245.16 -7.57 -2.99%
- Ticker
- BIIB
- Price
- $245.16
- Change
- -7.57 -2.99%
- Market cap ?
- $36.22B
- P/E ?
- 44.41
- Forward P/E ?
- 19.86
- Dividend yield ?
- 0.00%
- Beta ?
- 0.17
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stocklytics score
- 37
- Value
- 46
- Quality
- 47
- Growth
- 19
Stocklytics score rationale: value 46, quality 47, growth 19.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 11448800000 | 12273900000 | 13452900000 | 14377900000 | 13444600000 | 10981700000 | 10173400000 | 9835600000 | 9675900000 | 9810600000 |
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while…
Fair value
BIIB fair value $342.43. Price $245.16. Price is 28% below fair value.
Below fair value, and cheaper than usual. A larger discount than on 98% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 2.42B. Growth 13.54%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 147.75M. Net debt 3.94B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2027-02-05 | — | 3.14 | — | 2.61B |
| 2026-10-28 | 2.62 | 1.99 | 2.80B | 2.63B |
| 2026-07-29 | 3.60 | 2.94 | 2.74B | 2.46B |
| 2026-04-29 | 3.57 | 3.05 | 2.48B | 2.29B |
| 2026-02-06 | 1.99 | 1.63 | 2.28B | 2.20B |
| 2025-10-30 | 4.81 | 3.88 | 2.45B | 2.34B |
| 2025-07-31 | 5.47 | 3.90 | 2.65B | 2.33B |
| 2025-05-01 | 3.02 | 2.90 | 2.43B | 2.23B |
| 2025-02-12 | 3.44 | 3.43 | 2.45B | 2.41B |
| 2024-10-30 | 4.08 | 3.77 | 2.47B | 2.43B |
| 2024-08-01 | 5.28 | 4.07 | 2.35B | 2.39B |
| 2024-04-24 | 3.67 | 3.47 | 2.29B | 2.31B |
| 2024-02-13 | 2.95 | 3.16 | 2.39B | 2.47B |
| 2023-11-08 | 4.36 | 3.99 | 2.53B | 2.39B |
| 2023-07-25 | 4.02 | 3.77 | 2.46B | 2.37B |
| 2023-04-25 | 3.40 | 3.28 | 2.46B | 2.34B |
| 2023-02-15 | 4.05 | 3.48 | 2.54B | 2.45B |
| 2022-10-25 | 4.77 | 4.13 | 2.51B | 2.47B |
| 2022-07-20 | 5.25 | 4.06 | 2.59B | 2.47B |
| 2022-05-03 | 3.62 | 4.41 | 2.53B | 2.50B |
| 2022-02-03 | 3.39 | 3.32 | 2.73B | 2.62B |
| 2021-10-20 | 4.77 | 4.15 | 2.78B | 2.67B |
| 2021-07-22 | 5.68 | 4.57 | 2.77B | 2.68B |
| 2021-04-22 | 5.34 | 5.06 | 2.69B | 2.67B |
| 2021-02-03 | 4.58 | 4.93 | 2.85B | 3.02B |
| 2020-10-21 | 8.84 | 8.06 | 3.38B | 1.07B |
| 2020-07-22 | 10.26 | 8.03 | 3.68B | 2.88B |
| 2020-04-22 | 9.14 | 7.73 | 3.53B | 2.99B |
| 2020-01-30 | 8.34 | 8.02 | 3.67B | 3.53B |
| 2019-10-22 | 9.17 | 8.27 | 3.60B | 3.25B |
| 2019-07-23 | 9.15 | 7.53 | 3.62B | 2.98B |
| 2019-04-24 | 6.98 | 6.87 | 3.49B | 3.43B |
| 2019-01-29 | 6.99 | 6.72 | 3.53B | 3.40B |
| 2018-10-23 | 7.40 | 6.78 | 3.44B | 3.15B |
| 2018-07-24 | 5.80 | 5.22 | 3.36B | 3.02B |
| 2018-04-24 | 6.05 | 5.94 | 3.13B | 3.07B |
| 2018-01-25 | 5.26 | 5.44 | 3.31B | 3.43B |
| 2017-10-24 | 6.31 | 5.73 | 3.08B | 2.79B |
| 2017-07-25 | 5.04 | 4.41 | 3.08B | 2.69B |
| 2017-04-25 | 5.20 | 4.97 | 2.81B | 2.69B |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Godbout Sean | Buy | 27 | — | — |
| 2026-10-02 | Godbout Sean | Sell | 8 | $219.88 | 1.76K |
| 2026-10-02 | Godbout Sean | Sell | 27 | — | — |
| 2026-10-01 | Godbout Sean | Buy | 985 | — | — |
| 2026-09-01 | Parini Michael | Buy | 7.41K | — | — |
| 2026-08-04 | Minor Lloyd | Sell | 593 | $200.96 | 119.17K |
| 2026-08-03 | Parini Michael | Other | 0 | — | — |
| 2026-08-03 | Minor Lloyd | Sell | 593 | $203.34 | 120.58K |
| 2026-06-09 | HAWKINS WILLIAM A | Buy | 1.50K | — | — |
| 2026-06-09 | SHERWIN STEPHEN A | Buy | 1.50K | — | — |
| 2026-06-09 | Rowinsky Eric K | Buy | 1.50K | — | — |
| 2026-06-09 | Mantas Jesus B | Buy | 1.50K | — | — |
| 2026-06-09 | LANGER SUSAN | Buy | 1.50K | — | — |
| 2026-06-09 | Patolawala Monish D | Buy | 1.50K | — | — |
| 2026-06-09 | Pangalos Menelas N | Buy | 1.50K | — | — |
| 2026-06-09 | Pangalos Menelas N | Buy | 2.37K | — | — |
| 2026-06-09 | Pangalos Menelas N | Sell | 2.37K | — | — |
| 2026-06-09 | Minor Lloyd | Buy | 1.50K | — | — |
| 2026-06-09 | Freire Maria C | Buy | 2.00K | — | — |
| 2026-05-01 | Keeney Adam | Buy | 939 | — | — |
| 2026-05-01 | Keeney Adam | Sell | 455 | $187.06 | 85.11K |
| 2026-05-01 | Keeney Adam | Sell | 939 | — | — |
| 2026-04-01 | Godbout Sean | Buy | 181 | — | — |
| 2026-04-01 | Godbout Sean | Sell | 54 | $183.78 | 9.92K |
| 2026-04-01 | Godbout Sean | Sell | 181 | — | — |
| 2026-02-13 | Viehbacher Christopher | Buy | 38.02K | — | — |
| 2026-02-13 | Singhal Priya | Buy | 10.56K | — | — |
| 2026-02-13 | Murphy Nicole | Buy | 10.56K | — | — |
| 2026-02-13 | Kramer Robin | Buy | 8.45K | — | — |
| 2026-02-13 | Keeney Adam | Buy | 8.03K | — | — |
| 2026-02-13 | Izzar Rachid | Buy | 7.39K | — | — |
| 2026-02-13 | Grogan Jane | Buy | 8.45K | — | — |
| 2026-02-13 | Gregory Ginger | Buy | 8.03K | — | — |
| 2026-02-13 | Godbout Sean | Buy | 1.80K | — | — |
| 2026-02-13 | ALEXANDER SUSAN H | Buy | 8.45K | — | — |
| 2026-02-12 | Murphy Nicole | Buy | 3 | $195.03 | 585 |
| 2026-02-09 | Singhal Priya | Sell | 2.66K | $199.83 | 531.55K |
| 2026-02-06 | Viehbacher Christopher | Buy | 15.45K | — | — |
| 2026-02-06 | Viehbacher Christopher | Sell | 15.45K | — | — |
| 2026-02-06 | Viehbacher Christopher | Sell | 6.62K | $201.18 | 1.33M |
| 2026-02-06 | Viehbacher Christopher | Buy | 9.01K | — | — |
| 2026-02-06 | Viehbacher Christopher | Sell | 4.36K | $201.18 | 876.34K |
| 2026-02-06 | Viehbacher Christopher | Sell | 9.01K | — | — |
| 2026-02-06 | Singhal Priya | Buy | 4.68K | — | — |
| 2026-02-06 | Singhal Priya | Sell | 1.41K | $201.18 | 284.07K |
| 2026-02-06 | Singhal Priya | Sell | 4.68K | — | — |
| 2026-02-06 | Singhal Priya | Buy | 2.22K | — | — |
| 2026-02-06 | Singhal Priya | Sell | 1.06K | $201.18 | 212.45K |
| 2026-02-06 | Singhal Priya | Sell | 2.22K | — | — |
| 2026-02-06 | Murphy Nicole | Buy | 4.68K | — | — |
| 2026-02-06 | Murphy Nicole | Sell | 1.41K | $201.18 | 283.26K |
| 2026-02-06 | Murphy Nicole | Buy | 1.94K | — | — |
| 2026-02-06 | Murphy Nicole | Sell | 914 | $201.18 | 183.88K |
| 2026-02-06 | Murphy Nicole | Buy | 2.10K | — | — |
| 2026-02-06 | Murphy Nicole | Sell | 1.02K | $201.18 | 204.60K |
| 2026-02-06 | Murphy Nicole | Sell | 4.68K | — | — |
| 2026-02-06 | Murphy Nicole | Sell | 1.94K | — | — |
| 2026-02-06 | Murphy Nicole | Sell | 2.10K | — | — |
| 2026-02-06 | Kramer Robin | Buy | 3.51K | — | — |
| 2026-02-06 | Kramer Robin | Sell | 1.06K | $201.18 | 213.85K |
| 2026-02-06 | Kramer Robin | Buy | 703 | — | — |
| 2026-02-06 | Kramer Robin | Sell | 207 | $201.18 | 41.64K |
| 2026-02-06 | Kramer Robin | Buy | 789 | — | — |
| 2026-02-06 | Kramer Robin | Sell | 273 | $201.18 | 54.92K |
| 2026-02-06 | Kramer Robin | Sell | 3.51K | — | — |
| 2026-02-06 | Kramer Robin | Sell | 703 | — | — |
| 2026-02-06 | Kramer Robin | Sell | 789 | — | — |
| 2026-02-06 | Keeney Adam | Buy | 3.28K | — | — |
| 2026-02-06 | Keeney Adam | Sell | 3.28K | — | — |
| 2026-02-06 | Keeney Adam | Sell | 994 | $201.18 | 199.97K |
| 2026-02-06 | Keeney Adam | Buy | 1.80K | — | — |
| 2026-02-06 | Keeney Adam | Sell | 589 | $201.18 | 118.50K |
| 2026-02-06 | Keeney Adam | Sell | 1.80K | — | — |
| 2026-02-06 | Izzar Rachid | Buy | 3.04K | — | — |
| 2026-02-06 | Izzar Rachid | Sell | 775 | $201.18 | 155.91K |
| 2026-02-06 | Izzar Rachid | Buy | 1.80K | — | — |
| 2026-02-06 | Izzar Rachid | Sell | 458 | $201.18 | 92.14K |
| 2026-02-06 | Izzar Rachid | Buy | 2.04K | — | — |
| 2026-02-06 | Izzar Rachid | Sell | 805 | $201.18 | 161.95K |
| 2026-02-06 | Izzar Rachid | Sell | 3.04K | — | — |
| 2026-02-06 | Izzar Rachid | Sell | 1.80K | — | — |
| 2026-02-06 | Izzar Rachid | Sell | 2.04K | — | — |
| 2026-02-06 | Grogan Jane | Buy | 1.87K | — | — |
| 2026-02-06 | Grogan Jane | Sell | 584 | $201.18 | 117.49K |
| 2026-02-06 | Grogan Jane | Sell | 1.87K | — | — |
| 2026-02-06 | Grogan Jane | Buy | 1.39K | — | — |
| 2026-02-06 | Grogan Jane | Sell | 407 | $201.18 | 81.88K |
| 2026-02-06 | Grogan Jane | Sell | 1.39K | — | — |
| 2026-02-06 | Gregory Ginger | Buy | 3.75K | — | — |
| 2026-02-06 | Gregory Ginger | Sell | 1.13K | $201.18 | 227.74K |
| 2026-02-06 | Gregory Ginger | Buy | 1.80K | — | — |
| 2026-02-06 | Gregory Ginger | Sell | 666 | $201.18 | 133.99K |
| 2026-02-06 | Gregory Ginger | Buy | 1.64K | — | — |
| 2026-02-06 | Gregory Ginger | Sell | 791 | $201.18 | 159.13K |
| 2026-02-06 | Gregory Ginger | Sell | 3.75K | — | — |
| 2026-02-06 | Gregory Ginger | Sell | 1.80K | — | — |
| 2026-02-06 | Gregory Ginger | Sell | 1.64K | — | — |
| 2026-02-06 | Godbout Sean | Buy | 517 | — | — |
| 2026-02-06 | Godbout Sean | Sell | 180 | $201.18 | 36.21K |
| 2026-02-06 | Godbout Sean | Sell | 517 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 1.10K, holders +40 vs prior quarter. Ownership 97.18%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FMR LLC | 18.22M | 5.41M | +42.24% | 3.94B |
| BLACKROCK, INC. | 15.99M | 11.13K | +0.07% | 3.45B |
| PRIMECAP MANAGEMENT CO/CA/ | 15.15M | 397.00K | +2.69% | 3.27B |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.65M | 113.70K | +1.19% | 2.09B |
| STATE STREET CORP | 7.34M | 176.41K | +2.46% | 1.59B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.60M | 73.21K | +1.12% | 1.43B |
| GEODE CAPITAL MANAGEMENT, LLC | 4.45M | 106.69K | +2.46% | 957.94M |
| WELLINGTON MANAGEMENT GROUP LLP | 3.12M | 155.83K | +5.26% | 673.56M |
| NORGES BANK | 2.58M | 2.58M | New | 557.44M |
| MORGAN STANLEY | 2.41M | 240.33K | +11.07% | 520.98M |
| AQR CAPITAL MANAGEMENT LLC | 1.94M | 13.30K | +0.69% | 416.93M |
| JPMORGAN CHASE & CO | 1.82M | -192.87K | -9.57% | 394.95M |
| INVESCO LTD. | 1.80M | 58.69K | +3.36% | 389.76M |
| AMUNDI | 1.52M | 726.00K | +91.80% | 327.73M |
| LEGAL & GENERAL GROUP PLC | 1.49M | 143.46K | +10.63% | 322.64M |
| NORTHERN TRUST CORP | 1.43M | -17.09K | -1.18% | 308.86M |
| BOSTON PARTNERS | 1.26M | -436.65K | -25.68% | 272.85M |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 1.26M | -122.40K | -8.89% | 271.19M |
| GOLDMAN SACHS GROUP INC | 1.23M | 179.30K | +17.06% | 265.84M |
| DIMENSIONAL FUND ADVISORS LP | 1.15M | 69.45K | +6.44% | 248.17M |
| PACER ADVISORS, INC. | 1.12M | 462.57K | +70.04% | 242.63M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.12M | -31.73K | -2.76% | 241.48M |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 1.12M | 1.12M | New | 241.48M |
| BANK OF AMERICA CORP /DE/ | 1.12M | -40.14K | -3.47% | 241.17M |
| UBS GROUP AG | 1.03M | 506.70K | +96.80% | 222.57M |
Insights
- Revenue by product
- Revenue by region
| Period | Value |
|---|---|
| FY2010 | TYSABRI product: 900200000.0 |
| FY2011 | TYSABRI product: 1079500000.0 |
| FY2012 | TYSABRI product: 1135900000.0 |
| FY2013 | TYSABRI product: 1526500000.0 |
| FY2014 | TYSABRI product: 1959500000.0 |
| FY2015 | TYSABRI product: 1886100000.0 |
| FY2016 | SPINRAZA: 4600000.0, TYSABRI product: 1963800000.0 |
| FY2017 | SPINRAZA: 883700000.0, TYSABRI product: 1973100000.0 |
| FY2018 | Interferon: 2363000000.0, MS Product Revenues: 8595200000.0, SPINRAZA: 1724200000.0, TYSABRI product: 1864000000.0 |
| FY2019 | Interferon: 2101800000.0, MS Product Revenues: 8529300000.0, SPINRAZA: 2097000000.0, TYSABRI product: 1892200000.0 |
| FY2020 | Fumarate: 3905400000.0, Interferon: 1877500000.0, MS Product Revenues: 7832100000.0, SPINRAZA: 2052100000.0, TYSABRI product: 1946100000.0 |
| FY2021 | Fumarate: 2362300000.0, Interferon: 1566100000.0, MS Product Revenues: 6096700000.0, SPINRAZA: 1905100000.0, TYSABRI product: 2063100000.0 |
| FY2022 | Fumarate: 1997300000.0, Interferon: 1305400000.0, MS Product Revenues: 5430200000.0, SPINRAZA: 1793500000.0, TYSABRI product: 2030900000.0 |
| FY2023 | Fumarate: 1588800000.0, Interferon: 1105700000.0, MS Product Revenues: 4661900000.0, SPINRAZA: 1741200000.0, TYSABRI product: 1876900000.0 |
| FY2024 | Fumarate: 1595100000.0, Interferon: 968000000.0, MS Product Revenues: 4349800000.0, SPINRAZA: 1573200000.0, TYSABRI product: 1715000000.0 |
| FY2025 | Fumarate: 1426500000.0, Interferon: 945600000.0, MS Product Revenues: 4038900000.0, SPINRAZA: 1546800000.0, TYSABRI product: 1665400000.0 |
| Period | Value |
|---|---|
| FY2010 | Non-US: 1725700000.0, UNITED STATES: 1744400000.0 |
| FY2011 | Non-US: 1881300000.0, UNITED STATES: 1954800000.0 |
| FY2012 | Non-US: 1989300000.0, UNITED STATES: 2176800000.0 |
| FY2013 | Non-US: 1961300000.0, UNITED STATES: 1902400000.0 |
| FY2014 | Non-US: 2636700000.0, UNITED STATES: 2426600000.0 |
| FY2015 | Non-US: 2642700000.0, UNITED STATES: 2908200000.0 |
| FY2016 | Non-US: 2767500000.0, UNITED STATES: 3169400000.0 |
| FY2017 | Non-US: 3337600000.0, UNITED STATES: 3294000000.0 |
| FY2018 | Asia: 281200000.0, Europe: 3370300000.0, UNITED STATES: 1903400000.0 |
| FY2019 | Non-US: 4666000000.0, UNITED STATES: 6713800000.0 |
| FY2020 | Non-US: 4792100000.0, UNITED STATES: 5900100000.0 |
| FY2021 | Non-US: 5041200000.0, UNITED STATES: 3805700000.0 |
| FY2022 | Non-US: 4518500000.0, UNITED STATES: 3469300000.0 |
| FY2023 | Asia: 649400000.0, Europe: 2127400000.0, GERMANY: 868000000.0, UNITED STATES: 3141400000.0 |
| FY2024 | Non-US: 3976200000.0, UNITED STATES: 3237300000.0 |
| FY2025 | Non-US: 3571500000.0, UNITED STATES: 2372500000.0 |
Insights · Dividends · Forecast · Financials · Learn